KR100770775B1 - Functional drink for immune- enhancing and Manufacturing method thereof - Google Patents
Functional drink for immune- enhancing and Manufacturing method thereof Download PDFInfo
- Publication number
- KR100770775B1 KR100770775B1 KR1020060032003A KR20060032003A KR100770775B1 KR 100770775 B1 KR100770775 B1 KR 100770775B1 KR 1020060032003 A KR1020060032003 A KR 1020060032003A KR 20060032003 A KR20060032003 A KR 20060032003A KR 100770775 B1 KR100770775 B1 KR 100770775B1
- Authority
- KR
- South Korea
- Prior art keywords
- concentrate
- weight
- ginseng
- chitosan
- immune
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title abstract description 7
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000012141 concentrate Substances 0.000 claims abstract description 46
- 235000008434 ginseng Nutrition 0.000 claims abstract description 41
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 39
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 39
- 229920001661 Chitosan Polymers 0.000 claims abstract description 38
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 11
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 11
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 11
- 229940010454 licorice Drugs 0.000 claims abstract description 11
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract description 9
- 235000020510 functional beverage Nutrition 0.000 claims abstract description 8
- 229930003231 vitamin Natural products 0.000 claims abstract description 6
- 235000013343 vitamin Nutrition 0.000 claims abstract description 6
- 239000011782 vitamin Substances 0.000 claims abstract description 6
- 229940088594 vitamin Drugs 0.000 claims abstract description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 5
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 5
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 5
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 5
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 5
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 5
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 5
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 5
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 5
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 5
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 5
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000282374 Puma concolor Species 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 3
- 230000002766 immunoenhancing effect Effects 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 8
- 241000411851 herbal medicine Species 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000002075 main ingredient Substances 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 3
- 240000004371 Panax ginseng Species 0.000 description 37
- 230000000694 effects Effects 0.000 description 28
- 210000002540 macrophage Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001247821 Ziziphus Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000002391 anti-complement effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 108010008730 anticomplement Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 229930195722 L-methionine Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 229960002079 calcium pantothenate Drugs 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- -1 ammonium (NH 4 + ) ions Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000753 anti-hemolysin Effects 0.000 description 2
- 235000021425 apple cider vinegar Nutrition 0.000 description 2
- 229940088447 apple cider vinegar Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/154—Water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/218—Yeast extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
본 발명은 면역증강용 기능성 음료에 관한 것이다. 보다 상세하게는 홍삼농축액, 산삼배양근농축액, 한약재농축액 및 키토산을 주성분으로 하는 음료로서 홍삼농축액 0.8~1.5중량%, 산삼배양근농축액 0.01~0.05중량%와, 한약재는 대추농축액 0.7~1.5(v/v)%, 산사자, 당귀, 구기자, 감초의 농축액을 각각 0.1~0.7중량%, 키토산 0.016~0.064중량%, 키토올리고당 0.2~0.7중량% 및 효모추출분말 0.05~0.15중량%에 비타민, 구연산, 아미노산, 올리고당을 적당량 혼합하여 구성된다. The present invention relates to a functional beverage for immune boosting. More specifically, red ginseng concentrate, wild ginseng cultured root concentrate, herbal medicine concentrate and chitosan as main ingredients, red ginseng concentrate 0.8-1.5% by weight, wild ginseng cultured root concentrate 0.01-0.05% by weight, and herbal medicine 0.7-1.5 (v / v) ), 0.1 ~ 0.7% by weight, hawthorn, Angelica, goji berry and licorice concentrate, vitamins, citric acid, amino acid, amino acid, amino acid, amino acid, amino acid, amino acid, It consists of mixing an appropriate amount of oligosaccharide.
본 발명의 기능성음료는 세포주와 실험동물의 임상실험(in vitro, in vivo)을 통하여 특이적으로 면역력 증강 효과를 나타낸다.The functional beverage of the present invention specifically exhibits an immune enhancing effect through cell lines and clinical experiments of animals ( in vitro, in vivo ).
홍삼, 산삼 배양근, 키토산, 비장지표 Red ginseng, wild ginseng culture root, chitosan, spleen index
Description
도 1은 면역증강음료의 처리농도가 높아짐에 따라 대식세포 U937의 산성 인산화효소의 활성을 나타낸 것이다.Figure 1 shows the activity of the acidic kinase of the macrophage U937 as the treatment concentration of the immuno-enhanced beverage increases.
도 2는 면역증강음료의 농도에 따른 항보체 효과를 나타낸 것이다.Figure 2 shows the anti-complement effect according to the concentration of immuno-enhanced beverages.
도 3은 면역증강음료 투여 후 대식세포의 활성화를 in vivo 조건에서 측정한 결과를 나타낸 것이다.Figure 3 shows the results of measuring the activation of macrophages in vivo conditions after the administration of immuno-enhanced beverages.
도 4는 면역증강음료를 처리한 후 대식세포의 활성화를 in vitro 조건에서 측정한 결과를 나타낸 것이다.Figure 4 shows the results of measuring the activation of macrophages in vitro conditions after the treatment of immuno-enhanced beverages.
도 5는 면역증강음료 투여 후 비장의 변화 여부를 나타내는 비장 지표(spleen index)를 나타낸 것이다.Figure 5 shows the spleen index (spleen index) indicating whether the change in the spleen after administration of the immuno-enhanced beverage.
도 6은 면역증강음료 투여 후 마우스 혈액 내 백혈구 중에 임파구 비율을 나타낸 것이다.Figure 6 shows the lymphocyte ratio in the white blood cells of the mouse blood after administration of the immuno-enhanced beverage.
본 발명은 면역증강용 기능성 음료에 관한 것이다. 더욱 상세하게는 홍삼농축액, 산삼배양근농축액, 키토산 및 키토올리고당을 주성분으로 하여 한약재로서 대추, 산사자, 당귀, 구기자, 감초의 농축액 및 효모추출물, 비타민, 구연산, 아미노산, 올리고당을 적당량 혼합하여 구성된다.The present invention relates to a functional beverage for immune boosting. More specifically, red ginseng concentrate, wild ginseng cultured root concentrate, chitosan and chitooligosaccharide as main ingredients, it is composed by mixing the appropriate amount of jujube, mountain lion, Angelica, wolfberry, licorice concentrate and yeast extract, vitamin, citric acid, amino acid, oligosaccharide.
키토산은 게나 새우등의 갑각류, 곤충류의 껍질에서 추출된 천연 고분자 다당체로서 분자량이나 염의 종류, 탈아세틸화도를 달리한 많은 종류가 제조 유통되고 있다. 그 기능 또한 항균성, 보습성 및 응집성이 높고 지방흡착, 콜레스테롤 배설, 항균성, 면역증강, 식이 섬유질 기능 등 다양하여 농업, 축산, 식품, 화장품, 의약, 의료용 재료, 생화학, 환경오염물질 제어, 펄프 제지분야 등 여러 분야에 응용되고 있다. 특히 기능성 식품에 대한 관심이 급증하면서 다양한 기능을 갖는 키토산을 이용하여 키토산 쌀, 키토산 김치, 키토산 젓갈 또는 키토산을 첨가한 김 등이 생산되어 국내 시장뿐 아니라 미국, 캐나다, 호주 등에 수출하여 외화를 벌어들이고 있다. 이러한 식품에 적용된 키토산의 기능으로서는 지방흡착, 콜레스테롤 배설, 항균성, 대식세포의 수를 부활시켜 면역력을 증강시키는 기능 및 식이 섬유질 기능 등이 알려져 있다.Chitosan is a natural polymer polysaccharide extracted from shells of shellfish such as crabs and shrimps, and insects, and many kinds are produced and distributed with different molecular weights, salt types, and deacetylation degrees. Its functions are also antimicrobial, moisturizing and cohesive, and it has various functions such as fat adsorption, cholesterol excretion, antimicrobial activity, immunity enhancement, and dietary fiber function. It is applied to various fields such as field. In particular, as interest in functional foods has soared, chitosan rice, chitosan kimchi, chitosan pickled fish, or chitosan-added seaweed is produced using chitosan with various functions, and exported to the US, Canada, Australia and other countries to earn foreign currency. I'm listening. The functions of chitosan applied to such foods are known as fat adsorption, cholesterol excretion, antimicrobial activity, resiliency of macrophages to enhance immunity and dietary fiber function.
일반적으로 키토산은 폐수처리 응용분야, 농업 응용분야, 식품과 음료 응용분야, 화장품 응용분야, 보건 위생 응용분야, 섬유관련 응용분야, 의약품 응용분야 등 여러 분야에 폭넓게 사용되고 있다.In general, chitosan is widely used in various fields such as wastewater treatment applications, agricultural applications, food and beverage applications, cosmetic applications, health and hygiene applications, textile applications, and pharmaceutical applications.
키토산은 천연물 중 유일하게 암모늄(NH4 +) 이온을 가지고 있어 화학적으로 음이온과 결합하기 쉬운 성질을 가지고 있어서 체내에서 유해한 중금속, 세균, 바이러스, 다이옥신 등과 같은 음이온을 배출시키는 역할을 한다. 또한, 키토산은 과잉의 지방물질과 결합함으로써 소화기 계통에서 지방질 포획제로 작용하기 때문에 지방질과 콜레스테롤을 포획하여 체외로 배출시키는 것으로 알려져 있다. 뿐만 아니라, 키토산은 항균력 및 방어기작을 가지고 있어 식물체의 자기 보호기능을 향상시키며, 발아 촉진 능력에 기인하여 식물세포를 활성화시키는 기능을 한다.Chitosan is the only natural product that has ammonium (NH 4 + ) ions, which is easy to bind chemically with anions, and releases harmful anions such as heavy metals, bacteria, viruses, and dioxins in the body. In addition, chitosan is known to capture fat and cholesterol and release it to the outside because it acts as a fat trapping agent in the digestive system by combining with excess fatty substances. In addition, chitosan has antimicrobial activity and defense mechanisms, which enhances the self-protection function of plants and activates plant cells due to their ability to promote germination.
한편, 동물들의 면역시스템은 자율신경계의 지배하에 있는데 스트레스를 받으면 그 스트레스를 받는 장기에 자율신경 조절이 실조되어 혈액 중 면역세포의 수 즉, 백혈구의 수에 변화를 일으킨다. 백혈구는 크게 과립구와 임파구 2가지로 나누어지며, 이들이 적절한 비율을 유지하면서 면역기능을 수행한다. 과립구는 주로 진균, 대장균 등 덩치가 큰 세균을 제거하는 역할을 담당하며, 임파구는 미세한 세균, 바이러스와 암세포를 제거하는 역할을 담당한다. 그러나 몸이 피로하거나 스트레스를 받을 경우 교감신경이 긴장을 하게 되고 과립구의 수를 증가시킨다. 과립구는 체내에 침입한 세균을 살상하는 중요한 일을 하지만 너무 많아지면 몸에 해를 입힌다. 과잉 생산된 과립구는 진균 등을 과량으로 살상하고 역할을 다 한 후에 혈액을 타고 점막에 붙기도 하고 죽을 때는 활성산소가 만들어진다. 이 활성산소가 지나치게 많아지면 조직파괴가 확산되고 위나 장의 점막이 파괴되어 위암이나 대장 암, 폐암, 자궁암 등을 일으킨다. 임파구의 활동이 억제되어 바이러스성 질환과 암에 걸리기 쉽게 되며, 몸이 지나치게 안정이 될 경우에는 임파구가 비정상적으로 증가해 아토피성 피부염, 기관지천식, 알레르기성 비염 등 알레르기 질환을 일으키며, 바이러스의 침입에 과잉반응을 보여 가벼운 감기에도 심한 고열과 염증을 일으키게 된다. 따라서 백혈구 내 임파구와 과립구의 비율을 일정하게 유지시킴으로써, 면역력을 증강시킬 수 있으며 질병을 예방할 수 있다.On the other hand, animals' immune system is under the control of the autonomic nervous system, and when stressed, autonomic nervous system regulation is impaired in the organs under stress, causing changes in the number of immune cells in the blood, that is, the number of white blood cells. Leukocytes are largely divided into granulocytes and lymphocytes, and they perform immune functions while maintaining an appropriate ratio. Granulocytes are mainly responsible for removing large bacteria such as fungi and E. coli, and lymphocytes are responsible for removing microbes, viruses and cancer cells. However, when the body is tired or stressed, the sympathetic nerve becomes nervous and increases the number of granulocytes. Granulocytes do an important job of killing bacteria that have invaded the body, but too much can harm the body. Over-produced granulocytes kill fungi, etc. in excess, and then attach to the mucous membranes in the blood and die when free radicals are made. Too much of this free radical spreads tissue breakdown and destroys the mucous membranes of the stomach and intestines, resulting in gastric cancer, colon cancer, lung cancer, and uterine cancer. The activity of lymphocytes is suppressed, which makes them susceptible to viral diseases and cancer. If the body becomes too stable, lymphocytes increase abnormally, causing allergic diseases such as atopic dermatitis, bronchial asthma, and allergic rhinitis. Overreaction causes severe fever and inflammation even with a mild cold. Therefore, by maintaining a constant ratio of lymphocytes and granulocytes in white blood cells, it is possible to enhance immunity and prevent disease.
인삼은 식물학적으로 오갈피과(Araliacea), 인삼속(Panax)에 속하는 식물로서 주로 뿌리를 약용으로 이용한다. 세계적으로 여기에 속하는 식물 종은 6~7종이 알려지고 있으나 경제적으로 재배되어 인삼 시장에서 상품으로 유통되고 있는 인삼 종은 국내산, 중국산, 미국산으로 크게 3종류가 주종을 이루고 있다. 지리적으로 아시아 극동지역에 분포, 재배되고 있는 Panax ginseng C.A.Meyer의 식물명을 가진 인삼은 전통적으로 중국의 한방생약 중 가장 중요한 약용 재료로 이용되어 왔다.Ginseng is botanically belonging to the genus Araliacea and Panax ginseng, and its root is mainly used for medicinal purposes. There are six to seven species of plants belonging to the world, but three kinds of ginseng are economically cultivated and distributed as commodities in the ginseng market. Panax ginseng C.A.Meyer's botanical name, which is geographically distributed and cultivated in the Far East of Asia, has traditionally been used as the most important medicinal ingredient among Chinese herbal medicines.
인삼은 예로부터 여러 가지 질병의 치료와 기력회복 촉진에 놀라운 효과를 발휘해 왔고 이러한 인삼의 효능에 대하여 인삼의 약효성분과 약리적 효능을 탐구하기 위하여 광범위한 연구를 계속하고 있으며 지금까지 과학적으로 밝혀진 대표적 효능으로는 신체 조절 기능의 항상성 유지 작용이라 할 수 있으며 이러한 작용에 근거하여 항피로 및 항스트레스 작용, 항당뇨 작용, 혈압 조절 작용, 항암작용 두뇌기능 강화 등을 들 수 있으며 주로 면역기능 강화작용에 의한 효과에 의한 결과라고 판단된다. 이러한 인삼의 주요 유효 성분으로는 사포닌, 사포게닌, 폴리아세틸렌, 피라진 유도체, 말톨 등이 알려져 있는데 특히 산삼계통은 인삼계통에는 포 함되지 않은 인체에 유익한 성분들이나 함량이 많은 것으로 알려졌다. Ginseng has been incredibly effective in treating various diseases and promoting energy recovery since ancient times, and continues to research extensively to explore the efficacy and pharmacological effects of ginseng. It can be said to be the homeostatic function of body control function, and based on this action, it can be anti-fatigue and anti-stress action, anti-diabetic action, blood pressure control action, anti-cancer action and brain function enhancement. It is judged that it is a result by. The main active ingredients of ginseng are known saponins, sapongenins, polyacetylenes, pyrazine derivatives, maltol, etc. In particular, the ginseng line is known to have many beneficial ingredients or contents that are not included in the ginseng line.
산삼과 산삼 유래 장뇌삼은 인삼과 초기 기원은 같았을 지라도 인삼의 경우 육종기간이 짧고 효과보다는 양적인 생산성 증대를 목적으로 선별육종이 이루어진 관계로 유전자의 단순화로 인해 원래의 인삼 효능에 비해 그 효과가 매우 떨어짐을 직간접적으로 인정되고 있는데 반하여, 산삼이나 그 기원에 가까운 산삼 유래 장뇌삼은 복잡한 유전자적인 구조를 유지하고 있는 것으로 밝혀지고 있다. 이러한 관계로 산삼 또는 산삼 유래 장뇌삼의 경우는 구전되는 경이적인 효과뿐만 아니라 현대적인 분석방법에 의해서도 그 차이가 규명되고 있다. Although ginseng derived from wild ginseng and wild ginseng has the same origin as ginseng, ginseng has a short breeding period and has been screened for the purpose of quantitative productivity rather than effect. While it is recognized directly or indirectly, wild ginseng and wild ginseng derived from wild ginseng, which are close to their origin, have been found to maintain a complex genetic structure. In this regard, the difference between wild ginseng or wild ginseng derived from wild ginseng is not only phenomenal by oral effects but also by modern analysis methods.
따라서 키토산과 산삼 배양근을 함유하는 음료를 간편하게 음용할 수 있도록 개발하여 소비자에게 공급한다면 국민 건강 증진에 기여할 수 있을 것이다.Therefore, if a beverage containing chitosan and wild ginseng culture roots is easily developed and supplied to consumers, it may contribute to the improvement of national health.
한편, 본 발명의 종래 기술로서, 한국특허공개 10-2004-0096153(키토산 양생 발아 현미추출액을 함유하는 드링크 및 이의 제조방법)은 키토산 양생 발아 현미추출액을 함유하는 드링크제에 관한 것이고, 한국특허공개 10-2003-0010293(고분자량의 수용성 키토산을 함유하는 음료)은 중량평균분자량이 약 600,000인 고분자량의 수용성 키토산을 함유하는 음료에 관한 것으로 본 발명의 구성과 상이하다.On the other hand, as a prior art of the present invention, Korean Patent Publication No. 10-2004-0096153 (drinks containing chitosan curing germinated brown rice extract and a preparation method thereof) relates to a drink containing chitosan curing germinated brown rice extract, -2003-0010293 (beverage containing high molecular weight water soluble chitosan) relates to a beverage containing a high molecular weight water soluble chitosan having a weight average molecular weight of about 600,000 and is different from the constitution of the present invention.
본 발명은 상기한 바와 같은 종래 기술의 문제점을 해결하기 위해 제안된 것으로, 본 발명의 목적은 홍삼농축액, 산삼배양근농축액, 키토산을 주성분으로 함유하는 면역증강을 위한 기능성 음료를 제공하는데 있다. The present invention has been proposed to solve the problems of the prior art as described above, an object of the present invention is to provide a functional drink for immuno-enhancing containing red ginseng concentrate, wild ginseng cultured muscle concentrate, chitosan as a main component.
상기의 목적을 달성하기 위한 본 발명은 인삼류농축액, 한약재농축액 및 키토산을 주성분으로 하고 음료용 부형재와 정제수를 포함되는 것을 특징으로 하는 면역증강용 기능성 음료를 포함한다. The present invention for achieving the above object comprises a ginseng concentrate, a herbal medicine concentrate and chitosan as a main component, and includes an immune enhancing functional drink comprising a beverage excipient and purified water.
상기에서, 인삼류농축액은 홍삼 및 산삼배양근으로부터 추출한 농축액으로써 홍삼농축액 0.8~1.5중량%와 산삼배양근농축액 0.01~0.05중량%로 포함되는 것을 특징으로 한다. In the above, the ginseng concentrate is extracted from red ginseng and wild ginseng cultured root, characterized in that it comprises 0.8 ~ 1.5% by weight red ginseng concentrate and 0.01 ~ 0.05% by weight of wild ginseng cultured root concentrate.
상기에서, 한약재농축액은 대추, 산사자, 당귀, 구기자 및 감초로부터 추출한 농축액으로써 대추농축액 0.7~1.5중량%, 산사자농축액 0.1~0.7중량%, 당귀농축액 0.1~0.7중량%, 구기자농축액 0.1~0.7중량%, 감초농축액 0.1~0.7중량%로 구성되는 것을 특징으로 한다.In the above, the herbal medicine concentrate is extracted from jujube, hawthorn, Angelica, wolfberry and licorice, jujube concentrate 0.7-1.5% by weight, mountain lion concentration 0.1-0.7% by weight, Angelica concentrate 0.1-0.7% by weight, Goji berry concentrate 0.1-0.7% by weight , Licorice concentrate is characterized in that composed of 0.1 to 0.7% by weight.
상기에서, 키토산은 0.016~0.064중량%, 키토올리고당은 0.2~0.7%로 구성되는 것을 특징으로 한다.In the above, chitosan is characterized by consisting of 0.016 to 0.064% by weight, chitooligosaccharides of 0.2 to 0.7%.
상기에서, 음료용 부형재로 비타민, 구연산, 아미노산 및 올리고당류가 추가로 포함되는 것을 특징으로 한다.In the above, vitamins, citric acid, amino acids and oligosaccharides are further included as a beverage excipient.
또한, 본 발명은 홍삼, 산삼배양근, 대추, 산사자, 당귀, 구기자 및 감초로부터 각각의 성분을 열수 또는 에탄올로 추출한 후, 농축하여 각각의 농축액을 얻는 단계와, 각각의 농축액에 키토산용액, 키토올리고당 및 음료용 부형재를 혼합하는 단계와, 살균 및 여과하는 단계를 포함하는 것을 특징으로 한다.In addition, the present invention extracts each component from red ginseng, wild ginseng culture root, jujube, hawthorn, Angelica, goji berry and licorice with hot water or ethanol, and then concentrated to obtain each concentrate, chitosan solution, chitooligosaccharide in each concentrate And mixing the beverage excipient and sterilizing and filtering.
이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명의 면역증강용 기능성 음료는 다음과 같이 구성된다. 시중에서 인삼류, 한약재, 효모의 추출물을 구입하여 농축한 후 사용하거나 또는 이들 재료에 열수 또는 에탄올을 첨가하여 추출한 후 농축하여 이들의 농축물에 키토산, 비타민, 구연산, 아미노산, 올리고당류를 적당량 혼합하여 구성된다. Functional beverage for immunological enhancement of the present invention is configured as follows. Commercially available extracts of ginseng, herbal medicine, and yeast are concentrated and used or extracted by adding hot water or ethanol to these ingredients, and then concentrated and mixed with appropriate amounts of chitosan, vitamins, citric acid, amino acids and oligosaccharides. It is composed.
인삼류농축물은 6년근 홍삼을 시중(충남 금산)에서 구입하여, 1kg의 홍삼에 대하여 8배의 정제수를 가하여 12~24시간 동안 60~90℃로 가열하여 홍삼성분을 충분히 추출한다. 알코올로 추출할 경우에는 30~50℃의 에탄올로 8~12시간 동안 추출하거나 또는 시중에서 홍삼추출물을 구입하여 사용할 수도 있다. 홍삼추출물의 농도가 낮으므로 이를 1/3로 진공농축하여 홍삼농축물을 얻는다.The ginseng concentrate is purchased 6-year-old red ginseng in the market (Gumsan, Chungnam), and 8 times purified water is added to 1 kg of red ginseng and heated to 60-90 ° C for 12 to 24 hours to fully extract the red ginseng components. In the case of extraction with alcohol, it may be extracted with ethanol at 30 to 50 ° C. for 8 to 12 hours, or commercially available red ginseng extract may be used. Since the concentration of red ginseng extract is low, red ginseng concentrate is obtained by vacuum concentration to 1/3.
산삼배양근농축물은 시중(경동시장)에서 구입하여 사용하거나 산삼배양근을 구입하여 홍삼농축물과 같이 추출 및 농축하여 얻는다.Wild ginseng cultivated root concentrates can be purchased from the market (Gyeongdong Market) or purchased from wild ginseng cultivated roots and extracted and concentrated like red ginseng concentrates.
한약재 농축물로써, 정선된 대추, 산사자, 당귀, 구기자, 감초를 시중(경동시장)에서 구입하여 홍삼농축물과 같이 추출 및 농축하여 얻을 수 있다. As a herbal herb concentrate, selected jujube, mountain lion, Angelica, goji berry, and licorice can be purchased at the market (Gyeongdong Market) and extracted and concentrated like red ginseng concentrate.
키토산 용액은 고분자 키토산을 구입하여 약 6.5% 정도의 사과식초에 용해시켜서 약 2%의 키토산용액의 형태로 사용한다.The chitosan solution is obtained by dissolving the polymer chitosan in about 6.5% apple cider vinegar and using it in the form of about 2% chitosan solution.
효모추출분말은 시중에서 직접 구입하여 사용한다.Yeast extract powder is purchased directly from the market.
비타민은 비타민B1, 비타민B2, 나이아신, 판토텐산칼슘, 비타민B6를 시중에서 구입하여 사용한다.Vitamin is used by purchasing a vitamin B 1, vitamin B 2, niacin, calcium pantothenate, vitamin B 6 on the market.
산류로써 유기산은 구연산과, 아미노산은 L-시스테인과 L-메치오닌을 시중에서 구입하여 사용한다. 이소말토올리고당은 시중에서 구입하여 사용한다. As acids, organic acids are citric acid and amino acids are L-cysteine and L-methionine. Isomaltooligosaccharides are commercially available.
상기의 홍삼, 산삼배양근, 대추, 산사자, 당귀, 구기자 및 감초의 추출물을 농축한 각각의 농축액에 키토산용액, 키토올리고당 및 음료용 부형재를 혼합하여 60~80℃로 살균한 후, 여과기로 불순물을 제거하여 포장한다.Chitosan solution, chitooligosaccharides and beverage excipients were mixed with each concentrated solution of the red ginseng, wild ginseng culture root, jujube, mountain lion, Angelica, goji berry and licorice extract, and sterilized at 60-80 ° C., followed by impurities with a filter. Remove and pack.
본 발명의 기능성음료는 세포주와 실험동물의 임상실험(in vitro, in vivo)을 통하여 특이적으로 면역력 증강 효과를 나타낸다.The functional beverage of the present invention specifically exhibits an immune enhancing effect through cell lines and clinical experiments of animals ( in vitro, in vivo ).
이하 본 발명의 내용을 실시예를 통해 더욱 상세하게 설명하기로 한다. 다만, 이들 실시예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예로 한정되는 것은 아니다.Hereinafter, the contents of the present invention will be described in more detail with reference to Examples. However, these examples are only presented to understand the content of the present invention, but the scope of the present invention is not limited to these embodiments.
[실시예 1] 음료의 제조 Example 1 Preparation of Beverage
면역증강을 위한 기능성 음료의 제조를 위해 홍삼농축액, 산삼배양근농축액, 키토산을 주원료로 하여 표1과 같이 제조하였다. 각각의 성분을 적정량의 정제수에 완전히 녹인 다음 100중량%로 채웠다.For the preparation of functional beverages for immune enhancement, red ginseng concentrate, wild ginseng cultured muscle concentrate, and chitosan were prepared as shown in Table 1. Each component was completely dissolved in an appropriate amount of purified water and then charged to 100% by weight.
<표 1> 면역증강음료의 성분(중량%)<Table 1> Ingredients (% by weight) of immune enhancing beverage
6년근 홍삼을 시중(충남 금산)에서 구입하여 1kg의 홍삼에 대하여 3배의 정제수를 가하여 20시간 동안 70℃로 가열하여 홍삼성분을 충분히 추출하였다. 홍삼추출물의 농도가 낮으므로 이를 1/3로 진공 농축하여 사용하였다. 산삼배양근농축물은 시중(경동시장)에서 구입하여 홍삼농축물과 같이 추출 및 농축하여 사용하였다.Six-year-old red ginseng was purchased from the market (Gumsan, Chungnam), and three times purified water was added to 1 kg of red ginseng, and heated to 70 ° C. for 20 hours to sufficiently extract the red ginseng component. Since the concentration of red ginseng extract was low, it was used by vacuum concentration to 1/3. Wild ginseng cultivated root concentrate was purchased from the market (Gyeongdong Market) and extracted and concentrated like red ginseng concentrate.
한약재농축물은 정선된 대추, 산사자, 당귀, 구기자, 감초를 시중(경동시장)에서 구입하여 홍삼농축물과 같이 추출 및 농축하여 사용하고, 키토산 용액은 고분자 키토산을 구입하여 6.5% 사과식초에 용해시켜서 2% 키토산용액의 형태로 사용한 다.Herbal medicine concentrates are selected jujube, hawthorn, Angelica, goji berry and licorice from the market (Gyeongdong Market), extracted and concentrated like red ginseng concentrate, and chitosan solution is obtained by dissolving it in 6.5% apple cider vinegar. It is used in the form of 2% chitosan solution.
효모추출물은 시중에서 직접 구입하여 사용하였다.Yeast extract was purchased directly from the market.
비타민은 비타민B1, 비타민B2, 나이아신, 판토텐산칼슘, 비타민B6를 시중에서 구입하여 사용하였다. Vitamin B 1 , vitamin B 2 , niacin, calcium pantothenate, and vitamin B 6 were purchased commercially.
산류로써 유기산은 구연산과 아미노산은 L-시스테인과 L-메치오닌을 시중에서 구입하여 사용하였다.As acids, citric acid and amino acid, L-cysteine and L-methionine, were used in the market.
당류는 이소말토올리고당을 시중에서 구입하여 사용하였다.As the sugar, isomaltooligosaccharide was purchased commercially and used.
* 혼합공정 및 살균 여과공정:* Mixing process and sterilization filtration process:
홍삼, 산삼배양근, 대추, 산사자, 당귀, 구기자 및 감초의 추출물을 농축한 각각의 농축액에 키토산용액과 음료용 부형재를 혼합하여 80℃로 살균한 후, 여과기로 불순물을 제거하여 포장하였다.Chitosan solution and beverage excipients were mixed with each concentrated solution of red ginseng, wild ginseng cultured root, jujube, mountain lion, Angelica, goji berry and licorice, and sterilized at 80 ° C., and then packaged by removing impurities with a filter.
[실시예 2] 세포주를 이용한 면역증강음료에 의한 면역 증강의 in vitro 효능 검증Example 2 In vitro Efficacy Verification of Immune Enhancement by Immunostimulating Beverage Using Cell Lines
U937 세포주를 이용하여 실시예1에서 제조한 면역증강음료의 효능을 검증하였다.면역증강음료는 0, 50㎍/㎖ , 100㎍/㎖ , 150㎍/㎖ , 200㎍/㎖ 농도로 2시간 동안 처리한 후, 산성 인산화효소 측정(Acid phosphatase assay)을 이용하여 U937 세포주의 산성 인산화효소의 활성에 따른 리소좀(lysosome)의 양 측정하였다. 산성 인산화효소의 활성은 2mM 파라-니트로페닐인산(para-nitrophenyl phosphate, PNP)이 포함된 1M 소듐아세테이트(sodium acetate)를 이용하였으며, 3회 반복하여 실시하였다. 시료의 처리농도가 높아짐에 따라 U937의 산성 인산화효소의 활성이 증가하며, 처리농도가 200 ㎍/㎖일 때 활성이 1.5배나 증가하였다(도 1). 이로 미루어보아 본 발명의 면역증강음료는 대식세포의 활성화를 통해 면역 기능을 증가시킬 수 있는 것으로 사료된다.The efficacy of the immunopotentiated beverage prepared in Example 1 was verified using the U937 cell line. The immune-enhanced beverage was obtained at 0, 50 µg / ml, 100 µg / ml, 150 µg / ml and 200 µg / ml concentrations for 2 hours. After treatment, the amount of lysosome according to the activity of acid kinase of U937 cell line was measured by using an acid phosphatase assay. Acid kinase activity was performed using 1M sodium acetate containing 2 mM para-nitrophenyl phosphate (PNP) and repeated three times. As the treatment concentration of the sample increases, the activity of the acidic kinase of U937 increases, and when the treatment concentration is 200 ㎍ / ㎖ increased 1.5 times (Fig. 1). In view of this, it is believed that the immune-enhanced beverage of the present invention can increase immune function through activation of macrophages.
[실시예 3] 실험동물을 이용한 면역증강음료의 면역기능 증대의 in vivo 효능 검증[Embodiment 3] In the in vivo increase immune function of immune enhancing beverages using animal experiments Efficacy Verification
(1) 항보체 활성(1) anticomplement activity
보체들의 활성화에 미치는 영향을 파악하기 위하여 보체가 특이 항-적혈구항체(hemolysin) 존재 하에서 적혈구를 용해(hemolysis)시킬 수 있다는 특성을 이용한 보체결합반응(complement fixation test)이라는 항체 검사법을 이용하여서 보체의 활성화 정도를 측정하고 있다. To investigate the effects on complement activation, complement assays were performed using an antibody test called the complement fixation test, which uses the property that complement can hemolyse red blood cells in the presence of specific anti-hemolysin. The degree of activation is measured.
Normal human serum, GVB++ 그리고 sample을 동량 첨가하여 일차반응(37℃, 30분)한 후 100 배율로 희석한 다음 감작 혈구를 첨가하고 2차 반응(37℃, 1시간)하여 감작 혈구의 용혈 억제 정도를 흡광도 412㎚에서 측정한다.Normal human serum, GVB ++ and the same amount of sample was added to the primary reaction (37 ℃, 30 minutes), diluted to 100 magnification, sensitized blood cells were added and the secondary reaction (37 ℃, 1 hour) hemolysis of sensitized blood cells The degree of inhibition is measured at absorbance 412 nm.
항보체 활성이란 보체들의 활성화에 미치는 영향을 파악하기 위하여 보체가 특이 항-적혈구항체(hemolysin)존재 하에서 적혈구를 용해(hemolysis)시킬 수 있다는 특성을 이용한 보체결합반응(complement fixation test)이라는 항체 검사법을 이용하여서 보체의 활성화 정도를 측정하였다. Anti-complement activity is an antibody test called the complement fixation test that uses the property that complement can dissolve erythrocytes in the presence of specific anti-hemolysin. The degree of activation of complement was measured.
본 실험에서 도 2는 면역증강음료의 농도에 따른 항보체 효과를 나타낸 것이다. 농도 의존적으로 항보체 활성도 증가함을 알 수 있었고, 1000㎍/㎖에서 최대 활성을 나타내었다. 양성 대조구로 사용된 LPS(lipopolysaccharide)와 비교하였을 때 저농도(100, 500㎍/㎖)에서는 낮은 활성을 보였지만, 고농도(1000㎍/㎖) 에서는 양성 대조구보다 높은 활성을 보였다. 이 결과로 미루어 보아 본 시료는 높은 항보체 활성을 가지는 것으로 사료된다. In this experiment, Figure 2 shows the anti-complement effect according to the concentration of immuno-enhanced beverage. It was found that anti-complement activity was increased in a concentration-dependent manner, and showed maximum activity at 1000 µg / ml. Compared to the LPS (lipopolysaccharide) used as a positive control, low activity (100, 500㎍ / ㎖) showed low activity, but high concentration (1000㎍ / ㎖) showed higher activity than the positive control. As a result, it is considered that the sample has high anti-complement activity.
(2) 실험동물을 이용한 면역증대 효과(2) Immune boosting effect using experimental animals
실험동물:Experimental Animals:
본 실험에 사용된 동물은 웅성 5 주령의 BALB/C 마우스를 이용하였다. 실험기간 동안 물과 사료는 충분한 양을 공급하였고, 동물실험실은 온도 22℃, 습도 55%를 유지하였으며, 12시간 간격으로 light-dark cycle을 유도하였다.Animals used in this experiment were male 5 week old BALB / C mice. During the experiment, water and feed were supplied in sufficient quantities, and the animal laboratory maintained a temperature of 22 ° C. and a humidity of 55% and induced a light-dark cycle at 12 hour intervals.
시료의 조제:Preparation of Samples:
시료는 멸균된 생리식염수를 사용하여 조제하였으며 투여량은 마우스 ㎏당, 20㎎으로 하고, 대조군은 saline을 투여하였으며, 투여하지 않을 때는 냉장실에 보관하면서 사용하였다.Samples were prepared using sterile physiological saline, and the dosage was 20 mg / kg mice, the control group was administered saline, when not administered it was used while stored in the refrigerator.
대식세포 리소좀 효소의 활성 분석:Activity analysis of macrophage lysosomal enzymes:
실험동물을 각 군당 5마리씩으로 하여 실험실에서 전처리한 시료를 600㎕(1㎎/㎖)씩 매일 복강 주사한 후 2일과 3일이 경과한 후 혈액은 마우스를 단두하여 얻고 매크로파지는 복강세척으로 획득하여 실험에 적용하였다. Five animals per group were injected daily intraperitoneally with a laboratory pretreated sample of 600 µl (1 mg / ml), and after 2 and 3 days, blood was obtained by migrating mice and macrophages obtained by abdominal washing. Was applied to the experiment.
마우스 복강에서 회수한 대식세포(macrophage) 수가 1×106개/㎖이 되도록 RPMI-1640 배지에 재분산시키고, 이 분산액을 96-웰 플레이트의 각 웰에 200㎕씩 분주한 다음 37℃에서 2시간 동안 CO2 배양하여 대식세포를 웰에 고정시킨 후 각 웰에 RPMI-1640 완전배지(10% FBS 함유)를 가하여 24시간 동안 배양시킨 후 활성화된 대식세포에 0.1% Triton X-100을 첨가하여 세포막을 용해시켰다. 이때 분비되는 리소좀의 포스파타아제(phosphatase)의 양을 ELISA reader로 405nm에서 흡광도를 측정하여 대식세포의 활성능 정도를 나타내었다. Redispersed in RPMI-1640 medium so that the number of macrophage (macrophage) recovered from the mouse abdominal cavity was 1 × 10 6 cells / ml, and the dispersion was dispensed in 200 μl into each well of a 96-well plate, followed by 2 at 37 ° C. Incubate for 2 hours to fix macrophages in the wells, and then add RPMI-1640 complete medium (containing 10% FBS) to each well for 24 hours, and then add 0.1% Triton X-100 to activated macrophages. Cell membranes were lysed. At this time, the amount of phosphatase of lysosomal secreted was measured by absorbance at 405 nm with ELISA reader to indicate the degree of activity of macrophages.
대식세포의 활성화를 in vivo(생체 내) 조건에서 측정한 결과는 도 3에 나타난 바와 같다. 대조군인 생리식염수의 활성을 100%로 보았을 때 음료의 처리군이 137%의 대식세포의 활성 증강을 나타내었다(도 3). 상기의 결과로 보아 음료의 투여는 생체 내 조건에서 대식세포 증식능을 보이는 것으로 보이며, 이 시료가 생체 내에 면역능 증강효과가 있는 것으로 사료된다. 음성 대조구로는 생리식염수(Saline : 0.9% NaCl)를 사용하였다. The results of measuring the activation of macrophages in vivo (in vivo) are shown in FIG. 3. When the control group of physiological saline was seen as 100%, the treated group of the beverage showed an enhanced activity of macrophages of 137% (Fig. 3). As a result, the administration of the beverage seems to show a macrophage proliferation ability in vivo conditions, it is believed that this sample has an effect of enhancing the immune capacity in vivo. Saline (Saline: 0.9% NaCl) was used as a negative control.
또한, 대식세포의 활성화를 in vitro(생체 외) 조건에서 측정하였다. 음성 대조구로는 생리식염수(Saline: 0.9% NaCl)를 사용하고, 양성대조구로는 리포폴리사카라이드(lipopolysaccharide, LPS)를 사용하였다. 그 결과 100㎍/㎖의 농도에서 양성대조구로 사용된 그람(Gram) 음성균의 세포벽 성분인 리포폴리사카라이드(from E.coli 026:86, LPS)의 활성보다 높은 수준으로 나타났다(도 4). 상기의 결과로 보아 본 발명의 음료는 비교적 강한 대식세포 활성능을 가지고 있는 것으로 사료된다. In addition, the activation of macrophages was measured in vitro ( in vitro ) conditions. Saline (0.9% NaCl) was used as a negative control and lipopolysaccharide (LPS) was used as a positive control. As a result, it was found to be higher than the activity of lipopolysaccharide (from E. coli 026: 86, LPS), which is a cell wall component of Gram-negative bacteria used as a positive control at a concentration of 100 ㎍ / ㎖ (Fig. 4). As a result, the beverage of the present invention is considered to have a relatively strong macrophage activity.
대식세포는 이 물질을 서로 확인할 수 있는 서로 다른 수용체를 지니고 있기 때문에 상기 음료가 대식세포의 활성에 직접적으로 관여할 수도 있지만 보체나 다른 림프구를 통한 2차적 작용에 의한 것일 수도 있다. 따라서 상기 음료의 두 가지 면역 활성(항보체와 대식세포의 활성)의 결과를 종합해 볼 때, 이 시료는 면역증강의 효과가 있는 것으로 사료된다. 하지만, 이들의 면역증강효과가 상호 관련된 두 면역체계에서는 어떠한 방향으로 진행될지는 현재로선 명확하지는 않는다고 하겠다.Since macrophages have different receptors that can identify these substances, the beverage may be directly involved in the activity of macrophages, but may be due to secondary action through complement or other lymphocytes. Therefore, combining the results of the two immune activities (anti-complement and macrophage activity) of the beverage, this sample is considered to have the effect of boosting the immune system. However, it is not clear at this time which direction their immune-boosting effects will progress in the two interrelated immune systems.
음료를 처리한 후 비장의 변화 여부를 나타내는 지표로써 비장 지표(spleen index)를 이용하였다. 이 지표는 동물 전체무게로 비장무게를 나눈 후 100을 곱하여 나타내는데, 비장의 무게 변화를 나타내는 방법이다. 상기 음료를 처리한 마우스의 비장 지표를 측정한 결과 대조구(saline) 그룹에 비하여 8%의 증가를 보였다(도 5). 이것으로 보아 상기 음료는 비장세포 증식을 증가시키는 기능이 있는 것으로 사료된다. Spleen index was used as an indicator of the change in the spleen after treatment. This indicator is expressed by dividing the spleen weight by the total weight of the animal and multiplying by 100 to express the change in the weight of the spleen. As a result of measuring the spleen indices of the mice treated with the beverage, it showed an increase of 8% compared to the saline group (FIG. 5). It is believed that the beverage has a function of increasing splenocyte proliferation.
<표 2> 비장유래세포 및 대식세포의 수 Table 2: Number of Spleen-Derived Cells and Macrophages
*20㎎/㎏씩 마우스 복강에 투여하였다.20 mg / kg were administered to the mouse abdominal cavity.
또한, 면역증강음료를 3일간 복강투여 후 비장유래세포와 대식세포의 수를 측정한 결과 비장세포의 경우는 큰 변화양상을 나타내지 않았지만 대식세포의 경우 세포 수가 급격히 증가하는 것으로 나타났다. In addition, splenic-derived cells and macrophages were measured after 3 days of intraperitoneal administration of immune-enhanced beverages. However, splenocytes showed no significant change, but macrophages showed a sharp increase in cell numbers.
또한, 면역증강음료를 3일간 복강투여 후 혈액에서 림프구 수를 측정하였다. 그 결과 도 6에 나타난 바와 같이 백혈구 중에 임파구 수의 비율에서 면역증강음료 투여군이 생리식염수 투여군보다 높다는 것은 면역을 조절하는 임파구 수가 많으므로, 그만큼 면역 조절력이 높다고 판단할 수 있다(도 6: □;생리식염수, ■; 면역증강음료(20㎎/㎏ body weight)).In addition, lymphocyte counts were measured in the blood after 3 days intraperitoneal administration of immunopotentiated beverages. As a result, as shown in Figure 6, the immune-enhanced beverage-administered group in the ratio of lymphocytes in the white blood cells is higher than the physiological saline-administered group, since the number of lymphocytes that regulate immunity, it can be judged that the immune regulation is as high (Fig. 6 □; Physiological saline, immunity-enhanced beverages (20 mg / kg body weight).
이상에서 살펴본 바와 같이 본 발명은 세포주와 실험동물의 임상실험을 통하여 특이적으로 면역력 증강 효과를 나타내는 기능성음료로서 스트레스가 많은 직장인, 중장년기의 남자와 여자, 허약체질의 노인과 수험생 등에 좋은 음료를 제공할 수 있다.As described above, the present invention is a functional beverage exhibiting a specific immunity-enhancing effect through clinical experiments of cell lines and experimental animals, and is a good drink for stressful office workers, middle-aged men and women, elderly people with weak physical condition, and examinees. Can provide.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060032003A KR100770775B1 (en) | 2006-04-07 | 2006-04-07 | Functional drink for immune- enhancing and Manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060032003A KR100770775B1 (en) | 2006-04-07 | 2006-04-07 | Functional drink for immune- enhancing and Manufacturing method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070100560A KR20070100560A (en) | 2007-10-11 |
KR100770775B1 true KR100770775B1 (en) | 2007-10-26 |
Family
ID=38805416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060032003A KR100770775B1 (en) | 2006-04-07 | 2006-04-07 | Functional drink for immune- enhancing and Manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100770775B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100903161B1 (en) | 2007-09-21 | 2009-06-17 | 천지영농조합법인 | The beverage of ginseng and its manufacturing method |
KR101935689B1 (en) | 2017-09-12 | 2019-04-04 | 에스케이바이오랜드 주식회사 | Composition comprising mixture extract of jujube, licorice and platycodon for enhancing immune response |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101044352B1 (en) * | 2011-01-21 | 2011-06-29 | 함양군 | Beverage process using acer mono max liquid and mountaingrown ginseng |
KR101147922B1 (en) * | 2011-11-10 | 2012-05-24 | 주식회사 더마랩 | Cosmetic composition and skin beauty food |
CN103005553A (en) * | 2012-11-06 | 2013-04-03 | 天津科技大学 | Preparation method of traditional Chinese medicine compound beverage for boosting immunity |
CN105639339A (en) * | 2015-12-29 | 2016-06-08 | 珠海市金隆生物科技有限公司 | Fatigue-resistance and immunity-enhancement chitosan oligosaccharide beverage and preparation method thereof |
KR102401725B1 (en) * | 2021-11-12 | 2022-05-24 | 조현숙 | Herbal medicine composition with improved palatability and functionality, and method for preparing the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0142725B1 (en) * | 1995-02-11 | 1998-07-01 | 김광배 | Drinks containing chitosan |
KR20030087724A (en) * | 2002-05-09 | 2003-11-15 | 한국원자력연구소 | A propolis-containing mixture reducing damages induced by reactive oxygen and radiation and enhancing immune activity, and its preparation |
KR20040034333A (en) * | 2003-03-31 | 2004-04-28 | 주식회사뉴엘 | Formular for Immunostimulant Mixture of Red Ginseng Extracts and Natural Substances, and Food including its Mixture |
KR100440222B1 (en) | 2002-06-19 | 2004-07-14 | (주) 다정 | Red ginseng drink |
KR20050110456A (en) * | 2004-05-19 | 2005-11-23 | 서울보건대학산학협력단 | Chitosan having an immunity homeostasis and immunity enhancement agent |
-
2006
- 2006-04-07 KR KR1020060032003A patent/KR100770775B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0142725B1 (en) * | 1995-02-11 | 1998-07-01 | 김광배 | Drinks containing chitosan |
KR20030087724A (en) * | 2002-05-09 | 2003-11-15 | 한국원자력연구소 | A propolis-containing mixture reducing damages induced by reactive oxygen and radiation and enhancing immune activity, and its preparation |
KR100440222B1 (en) | 2002-06-19 | 2004-07-14 | (주) 다정 | Red ginseng drink |
KR20040034333A (en) * | 2003-03-31 | 2004-04-28 | 주식회사뉴엘 | Formular for Immunostimulant Mixture of Red Ginseng Extracts and Natural Substances, and Food including its Mixture |
KR20050110456A (en) * | 2004-05-19 | 2005-11-23 | 서울보건대학산학협력단 | Chitosan having an immunity homeostasis and immunity enhancement agent |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100903161B1 (en) | 2007-09-21 | 2009-06-17 | 천지영농조합법인 | The beverage of ginseng and its manufacturing method |
KR101935689B1 (en) | 2017-09-12 | 2019-04-04 | 에스케이바이오랜드 주식회사 | Composition comprising mixture extract of jujube, licorice and platycodon for enhancing immune response |
Also Published As
Publication number | Publication date |
---|---|
KR20070100560A (en) | 2007-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100770775B1 (en) | Functional drink for immune- enhancing and Manufacturing method thereof | |
CN102762597A (en) | Polysaccharide suitable to modulate immune response | |
CN104432035B (en) | The health nutrient composition and method of making the same of enhancing immunity and application | |
CN106668321A (en) | Preparation method of radix ginseng and Chinese wolfberry fruit composition, and product and application thereof | |
KR20150005430A (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
KR101168381B1 (en) | Immune activation of green tea hdrolysate and the preparation of food with active components | |
KR20180010961A (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
CN110585302A (en) | Traditional Chinese medicine combined granular tea for treating chronic pharyngitis and preparation method thereof | |
CN108014150B (en) | Application of natural medicine composition in preparing anti-hypoxia and anti-radiation medicine or food | |
WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
CN104667135A (en) | Pharmaceutical composition and health care product and preparation method | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
KR101740028B1 (en) | Composition for preventing, improving, or treating arthritis comprising Achyranthis Japonicae Radix and Scutellariae Radix or Achyranthis Japonicae Radix, Scutellariae Radix and Acanthopanacis Cortex | |
TW201919657A (en) | Compositions and methods for enhancing immunity | |
CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
CN109589400B (en) | Composition with neuroprotective effect | |
CN111387394A (en) | Sea-buckthorn solid beverage for enhancing immunity and inhibiting tumors and preparation method thereof | |
WO2007007994A1 (en) | Food composition for improving liver function comprising a lonicera caerulea l. var. edulis extract | |
KR100773889B1 (en) | Composition containing effective ingredient of liquefied medical herb extracts for hangover removal and manufacturing method of thereof | |
US9737583B2 (en) | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient | |
US20100074975A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract | |
RU2333677C2 (en) | Dietary supplement | |
CN109198635A (en) | A kind of health food and preparation method thereof with strengthen immunity function | |
KR100912412B1 (en) | Pharmaceutics of traditional chinese medicine of treating AIDS and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121022 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130806 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141020 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161122 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181022 Year of fee payment: 12 |